D RIED blood spots (DBSs) -drops of capillary whole blood collected on fi lter paper from a simple prick of the fi nger -provide a minimally invasive alternative to venous blood sampling that facilitates the collection of blood samples in home-based settings, by nonmedically trained personnel. Although the advantages of DBS in terms of sample collection, transport, and storage are substantial, care should be taken when using data obtained from DBS, as they are not identical to results obtained by more commonly applied methods using serum or plasma samples ( McDade, Williams, & Snodgrass, 2007 ) . DBSs are one of the 13 direct biological measures (biomeasures) collected in the National Social Life, Health, and Aging Project (NSHAP). These measures, which also include weight, waist circumference, height, blood pressure, smell, saliva collection, taste, a selfadministered vaginal swab for female respondents, " Get Up and Go, " distance vision, touch, and oral mucosal transudate (Orasure®) HIV test, were collected for analysis of measures associated with physiological functioning. The collection of biomeasures in conjunction with questionnaire items allows for the investigation of the interaction between the social, psychological, and environmental domains and their impact on health. The object of this paper is to provide pertinent information on the collection, transport, and laboratory analysis of DBS samples in NSHAP to promote the appropriate use of data derived from these samples.
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Methods
In order to minimize participant burden and to maximize participation, the NSHAP interview and biomeasure collection process was designed to be completed in approximately 2 hr. To stay within these time constraints and still obtain the maximum amount of information, it was necessary to modularize the design of the survey. As a result, approximately 5/6 of NSHAP participants (2,494) were asked to provide blood spots. Of those asked, 84.5% (2,105) agreed. However, due to collection diffi culties, blood spots were not collected from an additional 57 individuals who originally agreed to participate. As a result, DBSs were collected from a total of 2,048 individuals. Because of the variability in volume of blood available for analysis, the sample size for each analyte obtained from blood spots varies. A list of analytes obtained and the sample size for each analyte is listed in Table 1 .
DBS Collection Protocol
Blood spots were collected from free-fl owing capillary blood obtained by fi nger stick. The protocol is as follows:
1. Angle Respondent's hand below his/her lap. 2. Warm fi nger and stimulate circulation by gently kneading and squeezing the appropriate fi nger.
3. Ask Respondent to gently shake his/her hand a few times. 4. Wipe the index fi nger of the right hand with alcohol swab and wait a few seconds for the alcohol to dry (DO NOT blow on fi nger, wave hand, etc. to speed up drying). 5. Squeeze the fi nger just below the area to be pricked. 6. Firmly prick fi nger in the fl eshy part of the pad, just off the center. 7. IMMEDIATELY dispose of the lancet into the sharps container. 8. Allow blood to well on tip of fi nger. 9. If necessary, apply gentle pressure below the site of the prick. 10. Place fi rst drop in discard circle of fi lter papermarked D. 11. Place three (if possible) additional drops on fi lter paper. 12. DO NOT reblot the circles on the fi lter paper (except discard circle). 13. If unable to fi ll three spots (+ discard spot), prick another fi nger. Place fi rst drop in discard circle of fi lter paper (marked D) and place additional drops in remaining circles. 14. If necessary, ask Respondent to hold cotton ball on fi nger and apply pressure until bleeding stops. 15. Offer Respondent a bandage.
After collection of the blood spots, fi eld interviewers (FIs) were instructed to record in the computer the number of blood spots collected and fi nger pricks attempted and to set the fi lter paper aside and allow the blood spots to dry for the remainder of the interview. At the end of the interview, the FI was instructed to fl ip the cover of the fi lter paper over the blood spots and place the fi lter paper in a plastic bag with a desiccant pack. Upon returning home, the blood spots were removed from the bag and allowed to air dry overnight. They were then returned to the bag and stored at 4 °C until shipped.
Field Interviewer Training
The majority of FIs used for data collection in NSHAP did not have any previous medical training. However, most of them did have previous experience in fi eld interviewing. FIs were brought to a central location, in three groups, for 8 days of training. FIs were trained in preventing disease transmission and the use of universal precautions as well as the specifi c techniques necessary for blood spot collection. Although one of the key benefi ts of this method of blood collection is the minimal risk to both the participant and the collector, every effort was made to train the interviewers to minimize their exposure to potential risks. Further, only single-use safety lancets were used to prevent exposure to used lancet blades, FIs were well supplied with alcohol pads, and all materials were collected in biohazard and sharps containers and properly disposed.
Basic techniques in the use of lancets, the proper positioning of the fi nger stick, and proper application of the blood to the card were demonstrated to FIs in small groups during the larger NSHAP training. Individual FIs were then given time to practice on themselves and each other under the supervision of experienced training personnel. Additional time with training personnel was available for those who needed extra training. On the fi nal day of training, each FI was required to demonstrate adequacy in blood spot collection before training was considered complete.
Continual feedback on the quality of spots was also provided to the FIs throughout the study period. As the blood spots were received in the laboratory for analysis, the number, quality, and condition of the spots was recorded by trained personnel. If consistent problems with collection were observed for a single FI, he or she was contacted to discuss potential problems and techniques that could be used to improve the quality of the blood spot collection.
Key issues in the collection of DBSs. -Sample volume is a key issue in the usability of blood spots for biomeasure analysis. In order to obtain the maximum amount of blood, FIs were instructed to allow large drops of blood to pool on the fi nger before dropping them onto the fi lter paper with the goal of fi lling each of the fi ve premarked circles entirely. Analysis of DBSs typically requires that either a 3.2-mm or a 6.0-mm disk of dried blood be punched out of the fi lter paper. A full drop of blood provides suffi cient sample for either a 1-to 6.0-mm disk of dried blood or up to 7-to 3.2-mm disks. Smaller volumes collected means less sample is available for analysis. Further, proper techniques used for promoting blood fl ow were stressed during training. The idea that " some people just don't bleed well " was discouraged, and FIs were taught that with proper technique -including having the individual rigorously shake his/her hand before the stick and fi rmly pressing the lancet to the fi nger for maximum contact with the blade -fi ve drops of blood is possible from almost anyone.
In addition to volume, it is necessary that the blood be collected appropriately to ensure that the blood is absorbed evenly across the fi lter paper. This ensures that the analyte of interest is evenly distributed across the blood spot. It is necessary, therefore, for the blood to be freely dropped onto the fi lter paper. If the fi nger is touched to the fi lter paper or blood is blotted onto the fi lter paper, the blood cannot fl ow evenly across the paper matrix and the spot is not usable for most analyses. Further, if more than one drop is applied to the same area of the fi lter paper and the spots are doubled or overlapping, these spots are also unusable for most analyses. Upon careful examination of the spots, those that have been blotted or double spotted will appear asymmetric. Only spots that appear symmetric and circular on both sides of the fi lter paper are appropriate for most analyses. The exceptions to these general guidelines are spots that will be used for DNA extraction or for other analyses where quantifi cation of the analyte in question is not necessary. A more detailed discussion of important issues in the collection and use of DBSs can be found in McDade et al. (2007) . After drying, the blood spots were refrigerated until shipment to the laboratory for analysis. DBSs were shipped in batches to the laboratory every 2 weeks. Shipment within the United States of blood (including blood spots, plasma, and serum) requires samples to be labeled and shipped as " diagnostic specimens. " These samples must be packed with enough absorbable material to collect any sample leakage and packed in a sealed, leak-proof bag or container. This container must be packed inside an additional sealed container clearly marked as diagnostic specimens on the outside of the package. Diagnostic specimens can be shipped through commercial carriers or through standard U.S. mail when correctly packaged (contact the United States Department of Transportation [USDOT] or commercial shipper for details). Upon arriving in the laboratory, blood spot cards were catalogued, analyzed for quantity and quality, and frozen at − 25 °C until analysis.
Collection Results
There were no signifi cant differences between individuals who agreed to provide blood spots and those who refused with respect to gender, race, ethnicity, age, education, income, or marital status. There was also no difference between the two groups with respect to self-reported mental or physical health or the number of doctor visits reported by the participants. However, the experience of the FI did have an impact on the percentage of their participants who refused to provide blood spots. Of the 131 FIs, the average success rate (measured by percentage of total number of subjects asked who agreed to provide a DBS) was 84. However, interviewers had signifi cantly higher response rates if they had more than 2 years of survey experience (82% vs. 86%). Neither the race of the FIs nor the age of the FIs, relative to the age group of the NSHAP participants, was associated with their success rate.
Individuals who refused to participate in blood spot collection reported various reasons for doing so. However, these responses followed a few general themes. Of the 158 refusal responses noted, 25% refused because of a reported medical condition, most commonly due to blood thinners, recent blood work, or daily glucose checks due to diabetes. Of the remaining refusals, 20% reported unease with potential pain, fear of needles, or dislike of blood, and 17% reported that they (or in three cases a family member) did not think providing blood was appropriate or believed the measure was too invasive or dangerous.
DBS sample quality. -Each card contains fi ve preprinted circles of standard size (1/2-inch diameter) for suggested collection. Interviewers in this study were instructed to blot the fi rst drop on the fi lter paper in the rightmost circle. This spot will not be used for analysis and is not described in the current paper. Remaining spots are counted and measured (in relation to the size of punches possible), and any obviously blotted or double dropped spots are noted. Both individual spots and entire cards will be described. Spots are considered to be too small if they are not large enough to allow for a single small (3.2 mm) hole punch. Spots are considered good if they will allow for a single large (6 mm) hole punch. Spots are considered excellent if they fi ll the entire circle. For the purposes of the NSHAP study, one large and three small punches are required for analysis of proposed biomarkers. Cards are considered to be inadequate if they cannot support the necessary punches, adequate if they will support only the required punches, and excellent if they will support more than the required amount of punches. Statistical analysis in the following section was completed using STATA 9.2 (StataCorp, College Station, TX). A summary of DBS card quantity and average quantity of blood collected by each FI is presented in Table 2 .
Blood Spot Analysis
Biomarkers for analysis from DBSs in NSHAP were selected based on several criteria, including availability of a valid assay, cost, and relative value of the measure with respect to the objectives of the survey. Analytes quantifi ed in NSHAP DBS samples include C-reactive protein (CRP), antibodies to the Epstein -Barr virus (EBV), hemoglobin, and HbA1c. In most cases, there was more sample collected than used, allowing for the potential future use of these DBSs for more analyses. The consent process was designed with this in mind, and participants were asked for permission to store their DBS samples for future use. The majority of participants, 86%, agreed to allow storage of any remaining sample for future use. Many additional analytes have been obtained from DBS, and improvements in technology may result in new analyses or methods for analyses. However, length of storage and stability of a new analyte must be CRP. -CRP is an acute-phase protein and a nonspecifi c marker of infl ammation. CRP has been used as a marker of immune activation ( McDade, Burhop, & Dohnal, 2004 ) as well as a risk factor for cardiovascular disease ( Smith et al., 2004 ) . Although CRP is correlated with other biological indicators of health, it is independently related to cardiovascular risk, even when accounting for age, smoking, blood pressure, and diabetes and lipids ( Koenigh, Sund, Frohlich, & Fischer, 1999 ; Pai, Pischon, Ma, & Manson, 2004 ; Ridker, 2003 ; Ridker Cushman, Stampfer, Tracy, & Hennekens, 1997 ; Ridker, Rifai, Rose, Buring, & Cook, 2002 ) . CRP values were assayed using an enzyme-linked immunosorbent assay (ELISA) protocol previously developed for use with DBS ( McDade et al., 2004 ) . Validation studies indicate that the blood spot CRP method has a lower detection limit of 0.028 mg L − 1 and a high correlation between matched plasma and blood spot samples. These matched samples can be used to convert DBS results to plasma/serum equivalents using the linear regression equation reported in McDade et al. (2004) .
However, care should be taken when comparing DBS values with plasma or serum values, as the relationship will vary across analytic methods and may vary by population (e.g., Shirtcliff, Reavis, Overman, & Granger, 2001 ) . As reported in Pearson et al. ( 2003 ) , the Centers for Disease Control and Prevention (CDC) has recently recommended classifi cations of cardiovascular risk as derived from CRP values. Plasma or serum CRP values >10 mg L − 1 are presumed to represent the presence of acute, active infection and should be excluded from analyses that are using CRP as an indicator of chronic, low-grade infl ammation. Based on the relationship between DBS and plasma/serum CRP values evaluated as part of the DBS CRP assay validation, a DBS value of 8.6 mg L − 1 corresponds to a plasma/serum value of 10 mg L − 1 . Distribution of CRP levels in the NSHAP sample are provided in Table 3 .
EBV antibody. -EBV is a ubiquitous human herpes virus that may cause mononucleosis, although most primary infections are asymptomatic. EBV is present in at least 90% of humans, although rates of seropositivity are lower among younger individuals and in more affl uent populations. Once infected, an individual carries the virus for his or her entire life ( Callan, 2004 ) . Although most individuals remain asymptomatic, EBV has also been linked to chronic fatigue syndrome and some lymphomas ( Thompson & Kurzrock, 2004 ) . Increased levels of psychosocial stress have been associated with viral activation due to reductions in cellmediated immune function, and measuring antibodies to EBV therefore provides an indirect measure of an aspect of cell-mediated immune function ( Glaser et al., 1991 ( Glaser et al., , 1993 . Levels of immunoglobulin G antibody to the viral capsid antigen complex of the EBV were determined using an ELISA protocol previously validated for use with DBS ( McDade, Stallings, & Worthman, 2000 ) . Distribution of EBV levels in the NSHAP sample are provided in Table 4 .
HbA1c. -Glucose is a sugar molecule that circulates in blood until it is used by cells for energy. Effective control over glucose concentrations is important for health, and high blood sugar after fasting is a sign of diabetes. Hemoglobin (Hb) is the protein that carries oxygen in the blood, contained in red blood cells. Normally, a small percentage of the Hb molecules in red blood cells become glycosylated (that is, chemically linked to glucose). The percent of glycosylated hemoglobin (HbA1c) increases over time in response to higher concentrations of circulating glucose. HbA1c, thus, can provide an integrated measure of blood sugar levels over the past 2 -3 months. Recent work has linked elevated HbA1c levels to cardiovascular disease, independent of diabetes status (see Grant et al., 2004 ) . Here, HbA1c is used to measure long-term blood glucose control -useful as a marker of blood sugar regulation, and therefore of how well diabetes is being managed, and as a marker of " prediabetes " ( Yoshinaga & Kosaka, 1996 ) . An HbA1c level of >7% (in total Hb) is associated with diabetes ( Ford & Mokdad, 2003 ) . According to the 3rd wave of the National Health and Nutrition Examination Survey (NHANES III) , 4.2% of the total population have reached this level of HbA1c, whereas the percentage of those with diagnosed diabetes with >7% HbA1c is 56.4%. In a sample of inner-city residents, Grant et al. found that 3.4% of people without diabetes had elevated HbA1c levels ( Grant et al., 2004 ) . However, these associations have not been demonstrated for values HbA1c levels obtained from DBS samples. To prevent further glycosylation of hemoglobin after collection on fi lter paper, one spot on the fi lter paper was pretreated with a proprietary solution provided by Flexsite Diagnostics (Palm City, FL). Analyses of HbA1c values were determined at Flexsite Diagnostics using an in-house protocol developed for the Cobas Integra blood chemistry analyzer. Based on previous research, Flexsite reports high correlation of results when compared with clinical standard methods (see http://www.fl exsite.com/Professional_A1c. html for details). Distribution of HbA1c levels in the NSHAP sample are provided in Table 5 .
Hemoglobin. -Hemoglobin is the protein that carries oxygen to the blood, contained in red blood cells. Both high and low levels of hemoglobin signal defects in the balance of red blood cells in the blood. Anemia, indicated by hemoglobin defi ciency, is an increasing health concern in the United States. In older populations, anemia is an independent risk factor for death ( Lipschitz, 2003 ) and decline in physical performance ( Penninx et al., 2003 ) . It is associated with decrease in myocardial function ( Penninx et al., 2003 ) , poor outcomes in many chronic diseases ( Goodnough & Nissenson, 2004 ) , and muscle density ( Cesari et al., 2004 ) . Prevalence of anemia increases with age ( Penninx et al., 2003 ) , but estimated prevalence rates for older populations in the United States vary widely from 3.9% to 59.9% depending on the population studied and criteria used for defi ning anemia ( Beghe, Wilson, & Ershler, 2004 ) . Hemoglobin was quantifi ed in DBS samples using a colorimetric method based on the conversion of hemoglobin to cyanmethemoglobin in the presence of Drabkin's solution ( O'Broin & Gunter, 1999 ) . Distribution of hemoglobin levels in the NSHAP sample are provided in Table 6 .
Analytical Issues
Because of the modularized design, blood spots were not requested of all NSHAP participants, and other sections of the survey were not completed on all individuals from which blood spots were requested. For example, on 500 of the individuals from which blood spots were requested, no sensory function or " Get Up and Go " tests were administered. As a result, sample sizes might be signifi cantly different for analyses using these variables.
Care should be taken when attempting to compare values derived from DBS samples and other sources. Although these methods have been previously validated against clinical standards, such as plasma or serum, they are not equivalent to these methods, and the relationship may vary across populations ( Shirtcliff et al., 2001 ) . The source and method of comparison, sample size used for validation, and strength of statistical relationship should be considered before comparisons are made.
Conclusions
DBS sampling was used as an alternative to venipuncture in the NSHAP to obtain several biomeasures useful in the assessment of health and risk for development of chronic diseases. In most cases, this method proved to be a viable alternative to venipuncture for both FIs and study participants, although proper and suffi cient training for interviewers is vital to the success of this method. The feasibility of both collection and analysis of DBS provides results that are valid and useful in community-based studies. However, care should be taken when using these data because these methods are not directly comparable to clinically standard methods. By providing these measures, we hope that when combined with the breadth of available social measures and self-reported measures collected in NSHAP, we are providing useful and important data to explore in an attempt to understand health outcomes in aging adults. 
